Part of the skin and hair peptide hub: every topical and cosmetic peptide we cover, with its evidence grade.
Botulinum Toxin
A bacterial toxin used in tiny doses to quiet overactive muscles, glands and pain nerves
Botulinum toxin is a bacterial protein that stops nerve endings releasing acetylcholine. In measured doses it relaxes the muscle or gland it is injected into for months. Botox is approved for conditions from chronic migraine to overactive bladder, and every botulinum toxin label carries a boxed warning about the effect spreading beyond the injection site.
What is it?
Botulinum toxin binds to cholinergic nerve terminals and blocks the release of acetylcholine inside them, so the muscle or gland they serve goes quiet. It does this by cleaving SNAP-25, one of the SNARE proteins nerve endings need to release their contents, in sensory as well as motor nerves. It does not cross into the brain.
That sensory action explains its use in chronic migraine, where relaxing muscles alone cannot account for the benefit: blocking SNARE-dependent release also cuts the output of pain-signalling molecules such as substance P, CGRP and glutamate from nerve fibres. In the label's two trials, 155 to 195 units every 12 weeks cut headache days by 7.8 and 9.2 a month against 6.4 and 6.9 on placebo. The effect is specific to the chronic form: in episodic migraine the PRECLUDE trial found no benefit.
The Botox label is long. It covers overactive bladder and neurogenic bladder, prevention of chronic migraine, spasticity, cervical dystonia, severe underarm sweating, blepharospasm and strabismus, each with its own dose, from 100 units into the bladder wall to 50 units per armpit, and never more than 400 units in three months for an adult. Its boxed warning covers distant spread of toxin effect: weakness, double vision, swallowing and breathing difficulty, reported hours to weeks after injection.
Bladder use has a known price. Pooled trials show more urinary infections and a roughly sevenfold rise in urinary retention, sometimes needing self-catheterisation. Against a surgical sling for mixed incontinence it did about as well overall, but worse for stress leakage, and many women needed a repeat injection within a year.
Trials continue to widen its use. Early injection after stroke slowed contractures; injections eased painful foot dystonia in Parkinson's disease; a pilot in jaw-muscle pain reduced tender points; a phase 3 trial treated prominent neck bands. Some uses remain experimental, such as injection between the eyebrows for treatment-resistant depression.
Mechanism of Action
Botulinum toxin type A is a bacterial protein that cleaves SNAP-25 inside nerve terminals, blocking acetylcholine release at the injected muscle or gland (label).
SNAP-25 cleaved
The toxin enters motor and autonomic nerve terminals and cleaves SNAP-25, a protein needed to dock and release acetylcholine (label).
Muscle and gland quieted
Without acetylcholine release, the injected muscle relaxes and sweat glands stop secreting; the label calls it an acetylcholine release inhibitor and neuromuscular blocking agent.
Sensory nerves too
Blocking release from sensory fibres reduces substance P, CGRP and glutamate output, the proposed basis of its effect in chronic migraine.
Published Research
These are the studies that describe botulinum toxin, read from their PubMed abstracts: three randomised trials and two reviews of how it works.
Early after stroke
93 stroke patients with no arm function who developed spasticity within six weeks received onabotulinumtoxinA or saline. Spasticity was lower, contractures formed more slowly and fewer splints were needed in the treated group.
Prominent neck bands
In a phase 3 trial, 32.3% on onabotulinumtoxinA against 1.9% on placebo reached a two-grade improvement in platysma prominence at day 14; adverse events were similar and no swallowing problems were reported.
Jaw-muscle pain
In a pilot of 21 patients with muscular jaw disorders, toxin injections reduced facial pain, headache and tender points over 12 weeks, and tender points fell more than with saline.
Chronic migraine: pooled PREEMPT
Pooling 1,384 people with chronic migraine, 56.1% on onabotulinumtoxinA against 49.1% on placebo had fewer than 15 headache days a month in weeks 13 to 24; with continued open-label treatment, 81.1% did so by weeks 53 to 56.
Episodic migraine: PRECLUDE failed
In people with episodic migraine, neither 155 nor 195 units reduced monthly migraine days significantly more than placebo, and no secondary endpoint was met.
MUSA: against a sling for mixed incontinence
In 137 women with mixed urinary incontinence, overall symptom scores at six months did not differ significantly from a midurethral sling; the sling did better for stress symptoms, and 28.2% of the toxin group had a second injection within a year.
Bladder pain syndrome
In 47 patients with interstitial cystitis, intradetrusor onabotulinumtoxinA gave lower symptom scores than bladder instillations at two months, but the difference was gone by 6 to 9 months; 8% had urinary retention.
Painful foot dystonia in Parkinson's
In 33 people with Parkinson's disease, dystonia-related foot pain fell much more than on placebo at 6 and 12 weeks (75% responders against at most 11.8%), with no worsening of movement.
Resistant depression: where to inject
In 57 people with treatment-resistant depression, injection into the frown muscles of the glabella gave 44.8% responders against 17.9% for injection at the crow's feet; there was no placebo group.
How it works
Botulinum toxin binds cholinergic nerve terminals and blocks acetylcholine secretion, reduces muscle tone through the stretch reflex, blocks autonomic fibres to glands, and does not cross the blood-brain barrier.
Why it helps migraine
OnabotulinumtoxinA cleaves SNAP-25 in motor and sensory nerves, reducing release of substance P, CGRP and glutamate from pain fibres and the insertion of pain receptors into nerve membranes.
Bladder injections: the side effects
Across 26 randomised trials, intradetrusor injection raised urinary tract infection risk (relative risk 1.54 to 2.53) and urinary retention (about 7-fold), with more need to self-catheterise; the risks did not differ by dose.
Dosing Data
Botox doses are in units and differ by indication: 100 units into the bladder wall for overactive bladder, 155 units across seven head and neck muscles for chronic migraine, 50 units per armpit for sweating; adults never exceed 400 units in three months.
Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.
Side Effects & Contraindications
Reported Side Effects
From the Botox label and the trials above.
Contraindications & Cautions
Set by the labels.
Legal Status
Botulinum toxin products are FDA-approved biologics.
Frequently Asked Questions
?How does botulinum toxin work?
It cleaves SNAP-25 inside nerve endings, so they cannot release acetylcholine, and the injected muscle or gland relaxes.
?What is it approved for?
Botox's label includes chronic migraine, overactive bladder, spasticity, cervical dystonia, underarm sweating, blepharospasm and strabismus.
?What is the boxed warning?
Its effect can spread beyond the injection site, causing weakness, double vision, swallowing or breathing difficulty hours to weeks later.
?Why does it help migraine?
It also blocks release of pain-signalling molecules such as CGRP and substance P from sensory nerves.
?Does it work for episodic migraine?
No proven benefit. Its approval is for chronic migraine, 15 or more headache days a month. In the PRECLUDE trial in episodic migraine, neither 155 nor 195 units beat placebo.
References
- [fda-pi] BOTOX (onabotulinumtoxinA) for injection Prescribing Information, sections boxed warning, 1 and 2 (DailyMed version 62, effective November 18, 2023; read September 30, 2026).
- [pubmed] Lindsay C, et al. "Can the early use of botulinum toxin in post stroke spasticity reduce contracture development? A randomised controlled trial." Clin Rehabil, 2021;35(3):399-409. PMID: 33040610.
- [pubmed] Fabi S, et al. "Improvement of platysma prominence with onabotulinumtoxinA: Safety and efficacy results from a randomized, double-blinded, placebo-controlled phase 3 trial." J Am Acad Dermatol, 2025;92(2):285-291. PMID: 39442886.
- [pubmed] Kim SR, et al. "Effect of Botulinum Toxin on Masticatory Muscle Pain in Patients with Temporomandibular Disorders: A Randomized, Double-Blind, Placebo-Controlled Pilot Study." Toxins (Basel), 2023;15(10). PMID: 37888628.
- [pubmed] Dressler D, et al. "Botulinum toxin: mechanisms of action." Eur Neurol, 2005;53(1):3-9. PMID: 15650306.
- [pubmed] Burstein R, et al. "Mechanism of Action of OnabotulinumtoxinA in Chronic Migraine: A Narrative Review." Headache, 2020;60(7):1259-1272. PMID: 32602955.
- [pubmed] Jankovic J. "Botulinum toxin in clinical practice." J Neurol Neurosurg Psychiatry, 2004;75(7):951-7. PMID: 15201348.
- [other] US FDA, Drugs@FDA (openFDA): BOTOX and BOTOX COSMETIC (onabotulinumtoxinA), BLA 103000, Allergan, prescription. Read September 30, 2026.
- [pubmed] Silberstein SD, et al. "Sustained benefits of onabotulinumtoxinA treatment in chronic migraine: An analysis of the pooled Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT) randomized controlled trials." Headache, 2024;64(7):838-848. PMID: 38982666.
- [pubmed] Pozo-Rosich P, et al. "OnabotulinumtoxinA for the preventive treatment of episodic migraine: Results from the phase 3, multicenter randomized, double-blind, placebo-controlled phase of the PRECLUDE trial." Cephalalgia, 2025;45(10):3331024251370769. PMID: 41091731.
- [pubmed] Harvie HS, et al. "Midurethral Sling vs OnabotulinumtoxinA in Females With Urinary Incontinence: The MUSA Randomized Clinical Trial." JAMA, 2025;333(21):1887-1896. PMID: 40323617.
- [pubmed] Welch EK, et al. "Bladder instillations vs onabotulinumtoxinA injection for interstitial cystitis/bladder pain syndrome: a randomized clinical trial." Am J Obstet Gynecol, 2024;231(5):528.e1-528.e11. PMID: 38768800.
- [pubmed] Mahjoub Y, et al. "OnabotulinumtoxinA for Painful Foot Dystonia in Parkinson Disease: A Randomized, Double-Blind, Placebo-Controlled Trial." Neurol Clin Pract, 2026;16(6):e200659. PMID: 42753227.
- [pubmed] Ceolato-Martin C, et al. "OnabotulinumtoxinA in Resistant Depression: A Randomized Trial Comparing Two Facial Injection Sites (OnaDEP Study)." Depress Anxiety, 2024;2024:1177925. PMID: 40226647.
- [pubmed] Yu PH, et al. "Adverse Effects of Intravesical OnabotulinumtoxinA Injection in Patients with Idiopathic Overactive Bladder or Neurogenic Detrusor Overactivity: A Systematic Review and Meta-Analysis of Randomized Controlled Studies." Toxins (Basel), 2024;16(8). PMID: 39195753.
Sources & Citations
Studies were read from their PubMed abstracts; the Botox label (DailyMed version 1, effective February 2, 2026) was read October 6, 2026.
Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Talk to a licensed clinician about your own situation.